U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Some reading about my myeloma specialist's success rate. A press release and an article from Targeted Oncology.
No comments:
Post a Comment